Jean-Luc Canon

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Henri Roché, P. Fumoleau, M. Spielmann et al. · Journal of Clinical Oncology · 2006 · 570 citations · Full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery

Patrice Forget, Jean‐Pascal Machiels, Pierre G. Coulie et al. · Annals of Surgical Oncology · 2013 · 168 citations

Surgical Oncology, Patients Undergoing Breast, Medicine +8

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

Pascal Jézéquel, Olivier Kerdraon, Hubert Hondermarck et al. · Breast Cancer Research · 2019 · 114 citations · Full text

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa et al. · Journal of Clinical Oncology · 2023 · 87 citations · Full text